Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”

Sander van Doorn; Frans H. Rutten; Geert Jan Geersing

doi:10.1161/CIRCULATIONAHA.124.070172

Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”

Sander van Doorn, Frans H. Rutten, Geert Jan Geersing

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Article number	124.070172
Pages (from-to)	e30-e32
Journal	Circulation
Volume	150
Issue number	2
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.124.070172
Publication status	Published - 9 Jul 2024

Access to Document

10.1161/CIRCULATIONAHA.124.070172

Cite this

van Doorn, S., Rutten, F. H., & Geersing, G. J. (2024). Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”. Circulation, 150(2), e30-e32. Article 124.070172. https://doi.org/10.1161/CIRCULATIONAHA.124.070172

van Doorn, Sander ; Rutten, Frans H. ; Geersing, Geert Jan. / Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation : Results of the FRAIL-AF Randomized Controlled Trial”. In: Circulation. 2024 ; Vol. 150, No. 2. pp. e30-e32.

@article{1d7914b3bb6d45b09e35bf295d1961e2,

title = "Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”",

author = "{van Doorn}, Sander and Rutten, {Frans H.} and Geersing, {Geert Jan}",

year = "2024",

month = jul,

day = "9",

doi = "10.1161/CIRCULATIONAHA.124.070172",

language = "English",

volume = "150",

pages = "e30--e32",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "2",

}

van Doorn, S , Rutten, FH & Geersing, GJ 2024, 'Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”', Circulation, vol. 150, no. 2, 124.070172, pp. e30-e32. https://doi.org/10.1161/CIRCULATIONAHA.124.070172

Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”. / van Doorn, Sander ; Rutten, Frans H.; Geersing, Geert Jan.
In: Circulation, Vol. 150, No. 2, 124.070172, 09.07.2024, p. e30-e32.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation

T2 - Results of the FRAIL-AF Randomized Controlled Trial”

AU - van Doorn, Sander

AU - Rutten, Frans H.

AU - Geersing, Geert Jan

PY - 2024/7/9

Y1 - 2024/7/9

UR - http://www.scopus.com/inward/record.url?scp=85198105405&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.124.070172

DO - 10.1161/CIRCULATIONAHA.124.070172

M3 - Comment/Letter to the editor

C2 - 38976611

AN - SCOPUS:85198105405

SN - 0009-7322

VL - 150

SP - e30-e32

JO - Circulation

JF - Circulation

IS - 2

M1 - 124.070172

ER -

van Doorn S , Rutten FH , Geersing GJ. Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”. Circulation. 2024 Jul 9;150(2):e30-e32. 124.070172. doi: 10.1161/CIRCULATIONAHA.124.070172

Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”

Access to Document

Other files and links

Cite this